WS Investor
05 Oct 2026, 14:20
Genmab Stock Rises 3.2% as Guggenheim Raises Price Target Following Positive Rina-S Data
Genmab shares rose 3.2% to $35.87 after Guggenheim raised its price target to $54 from $45 while maintaining a Buy rating.
The more bullish view follows encouraging Phase 1/2 RAINFOL-01 data for rinatabart sesutecan, or Rina-S, in platinum-resistant ovarian cancer. Among 109 treated patients, Rina-S produced a confirmed objective response rate of 45.9%, including five complete responses, with a median duration of response of 12.1 months. Median progression-free survival reached 9.5 months.
Importantly, antitumor activity was observed regardless of folate receptor alpha expression levels, including patients with low or no detectable expression, potentially broadening the addressable patient population. Activity was also seen regardless of prior treatment with mirvetuximab.
The safety profile appeared manageable, with treatment discontinuation due to adverse events reported in 5.5% of patients and no observed safety signals for ocular toxicity, peripheral neuropathy, interstitial lung disease or stomatitis.
The results strengthen the outlook for Rina-S as Genmab advances four Phase 3 trials across ovarian and endometrial cancer. Guggenheim’s higher target likely reflects increased confidence in the asset’s clinical and commercial potential as the program moves deeper into late-stage development.
Genmab shares rose 3.2% to $35.87 after Guggenheim raised its price target to $54 from $45 while maintaining a Buy rating.
The more bullish view follows encouraging Phase 1/2 RAINFOL-01 data for rinatabart sesutecan, or Rina-S, in platinum-resistant ovarian cancer. Among 109 treated patients, Rina-S produced a confirmed objective response rate of 45.9%, including five complete responses, with a median duration of response of 12.1 months. Median progression-free survival reached 9.5 months.
Importantly, antitumor activity was observed regardless of folate receptor alpha expression levels, including patients with low or no detectable expression, potentially broadening the addressable patient population. Activity was also seen regardless of prior treatment with mirvetuximab.
The safety profile appeared manageable, with treatment discontinuation due to adverse events reported in 5.5% of patients and no observed safety signals for ocular toxicity, peripheral neuropathy, interstitial lung disease or stomatitis.
The results strengthen the outlook for Rina-S as Genmab advances four Phase 3 trials across ovarian and endometrial cancer. Guggenheim’s higher target likely reflects increased confidence in the asset’s clinical and commercial potential as the program moves deeper into late-stage development.
